Improving intracellular doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids

Pharmaceutical Research

Volumn 30, Issue 7, 2013, Pages 1883-1895

  Pedrosa, Lília R Cordeiro ^a   Van Hell, Albert ^b   Süss, Regine ^c   Van Blitterswijk, Wim J ^b   Seynhaeve, Ann L B ^a   Van Cappellen, Wiggert A ^a   Eggermont, Alexander M M ^a,d   Ten Hagen, Timo L M ^a   Verheij, Marcel ^b   Koning, Gerben A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

doxorubicin nanoliposome; short chain sphingolipid; Tumor cell membrane permeabilization

Indexed keywords

C8 GALACTOSYLCERAMIDE; C8 GLUCOSYLCERAMIDE; C8 LACTOSYLCERAMIDE; DOXORUBICIN; LIPOSOME; NANOLIPOSOME; SPHINGOLIPID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RETENTION; DRUG STABILITY; DRUG UPTAKE; ENCAPSULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR CELL;

EID: 84878837344     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1031-6     Document Type: Article

References (40)

1. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal dox: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419-36. (Pubitemid 36649037)
2. Koning GA, Krijger GC. Targeted multifunctional lipid based nanocarriers for image guided drug delivery. Anti Cancer Agents Med Chem. 2007;7(4):425-40. (Pubitemid 47099049)
3. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Contr Release. 2000;65(1-2):271-84. (Pubitemid 30122932)
4. Mayer D, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumor activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol. 1993;33(1):17-24. (Pubitemid 23336495)
5. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated Dox tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 1999;53(2-3):183-90.
6. Veldman RJ, Zerp S, van Blitterswijk WJ, Verheij M. N-hexanoyl- sphingomyelin potentiates in vitro Dox cytotoxicity by enhancing its cellular influx. Br J Cancer. 2004;90(4):917-25. (Pubitemid 38406607)
7. Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, et al. Coformulated N-Octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal Dox. J Pharmacol Exp Ther. 2005;315(2):704-10. (Pubitemid 41500736)
8. van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, et al. Enriching lipid nanovesicles with short-chain glucosylceramide improves Dox delivery and efficacy in solid tumors. FASEB J. 2011;25(10):280-9.
9. Jacobson K, Mouritsen OG, Anderson RG. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol. 2007;9(1):7-14. (Pubitemid 46024188)
10. Anderson RG. The caveolae membrane system. Annu Rev Biochem. 1998;67:199-225. (Pubitemid 28411129)
11. Masserini M, Ravasi D. Role of sphingolipids in the biogenesis of membrane domains. Biochim Biophys Acta. 2001;1532(3):149-61. (Pubitemid 32706435)
12. Siskind LJ, Colombini M. Sphingosine forms channels in membranes that differ greatly from those by ceramide. J Bioenerg Biomembr. 2005;37(4):227-36. (Pubitemid 41420459)
13. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, et al. DNA Topoisomerase II-mediated interaction of Dox and daunorubicin congeners with DNA. Cancer Res. 1989;49(21):5969-78. (Pubitemid 19274156)
14. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727-41. (Pubitemid 29094544)
15. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine. 2007;2(4):567-83.
16. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. CAELYX Breast Cancer Study Group, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal Dox HCl (CAELYX/Doxil®) versus conventional Dox for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-9. (Pubitemid 38444547)
17. Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov Jr AA, Trubetskoy VS, Herron JN, et al. Poly (ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994;1195(1):11-20. (Pubitemid 24318086)
18. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal Dox versus Dox, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445-51. (Pubitemid 28309039)
19. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther. 2002;2(2):143-50. (Pubitemid 34679469)
20. Hussein MA, Anderson KC. Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol. 2006;31(6 Suppl 13):147-60.
21. Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, et al. Randomized trial of pegylated liposomal Dox (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol. 2008;108(1):90-4. (Pubitemid 350299426)
22. Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, Wiel-Ambagtsheer G, van Tiel ST, et al. Tumor necrosis factor a mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res. 2007;67(19):9455-62. (Pubitemid 47535935)
23. Laginha KM, Verwoert S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11(19 Pt 1):6944-9. (Pubitemid 41428752)
24. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37(7):870-7. (Pubitemid 32323965)
25. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151(2):201-15. (Pubitemid 23283973)
26. Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970;5(5):494-6.
27. Li X, Hirsh DJ, Cabral-Lilly D, Zirkel A, Gruner SM, Janoff AS, et al. Dox physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta. 1998;1415(1):23-40. (Pubitemid 29050759)
28. Maurer-Spurej E, Wong KF, Maurer N, Fenske DB, Cullis PR. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim Biophys Acta. 1999;1416(1-2):1-10. (Pubitemid 29065419)
29. Jaffe EA, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52(11):2745-56.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82(13):1107-12. (Pubitemid 20213250)
31. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, et al. Rapid distribution of liposomal short chain ceramide in vitro and in vivo. Drug Metab Dispos. 2008;36(8):1709-15.
32. Charrois GJ, Allen TM. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta. 2003;1609(1):102-8. (Pubitemid 36044071)
33. Bandekar A, Karve S, Chang M, Mu Q, Rotolo J, Sofou S. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin. Biomaterials. 2012;33:4345-52.
34. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992;52(12):3255-61.
35. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52(4):891-6.
36. Perez-Soler R, Ling YH, Zou Y, Priebe W. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. Cancer Chemother Pharmacol. 1994;34(2):109-18. (Pubitemid 24157974)
37. Koning GA, Morselt HW, Velinova MJ, Gorter A, Allen TM, Zalipsky S, Et al.,Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta. 1999;1420(1-2):153-67. (Pubitemid 29369027)
38. Koning GA, Gorter A, Scherphof GL, Kamps JA. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells. Br J Cancer. 1999;80(11):1718-25. (Pubitemid 29389623)
39. Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther. 2005;3(4):705-15. (Pubitemid 41086826)
40. Pinnaduwage P, Huang L. Stable Target-Sensitive immunoliposomes. Biochemistry. 1992;31:2850-5.